# TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

> **NCT04489173** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Borstkanker Onderzoek Groep** · enrollment: 52 (actual)

## Conditions studied

- Breast Neoplasm
- Chemotherapy Effect

## Interventions

- **DRUG:** trifluridine/tipiracil

## Key facts

- **NCT ID:** NCT04489173
- **Lead sponsor:** Borstkanker Onderzoek Groep
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-25
- **Primary completion:** 2024-01-08
- **Final completion:** 2025-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489173, "TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04489173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*